← All trials
NCT06323655
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2018
- Primary completion
- Aug 28, 2018
- Completion date
- Aug 28, 2018
- First posted
- Mar 21, 2024
- Last posted
- Mar 21, 2024
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanda PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.